Login to Your Account



Viropharma's Sub-cu Effort

Halozyme Stock Dented on Halting of Cynryze Phase II

By Randy Osborne
Staff Writer

Thursday, August 1, 2013

Skittish investors seemed more worried than analysts about word from Halozyme Therapeutics Inc. and Viropharma Inc. that the Phase II study will be discontinued with subcutaneous Cinryze (C1 esterase inhibitor with recombinant hyaluronidase [rHuPH20]) for hereditary angioedema (HAE) because of high levels of non-neutralizing antibodies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription